New drug cocktail targets tough lung cancer
NCT ID NCT07669779
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new drug called AK146D1, given together with other cancer drugs, in 348 people with advanced non-small cell lung cancer that cannot be surgically removed. The study aims to see if the combination is safe and can shrink tumors. Participants will receive the drugs by injection or infusion, and researchers will monitor side effects and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK146D1 (a bispecific antibody-drug conjugate targeting Trop2 and Nectin4) combined with AK112 (a bispecific antibody targeting PD-1 and VEGF) or other anticancer drugs
What this could lead to
If successful, this could provide a new treatment option for advanced non-small cell lung cancer that has not responded to other therapies.
What could go wrong
This is an early phase 2 trial, so the combination may not prove effective or safe enough for wider use. Side effects from the drug combination are possible and being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
SunYat-sen University Cancer Center
Guangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••